FTC Probes Express Scripts Deal for Market Fairness
Published Date: 2/12/2026
Notice
Summary
The Federal Trade Commission is reviewing a deal with Express Scripts and others to stop unfair business practices. This affects healthcare companies and could change how they compete, aiming for a fairer market. People have until March 16, 2026, to share their thoughts before the deal is final.
Analyzed Economic Effects
9 provisions identified: 8 benefits, 0 costs, 1 mixed.
Caps member costs to a drug's net price
If a plan sponsor adopts Express Scripts' required "standard offering," members' out-of-pocket costs for drugs must be no higher than the drug's net cost and cannot be tied to a higher list price. The Proposed Order requires this protection in the standard offering and says Cigna's fully‑insured health plans must adopt the same protections.
Cigna fully‑insured plans must adopt protections
All of Cigna's fully‑insured health plans are required by the Proposed Order to adopt the patient cost protections that limit member out-of-pocket costs to no more than a drug's net cost.
Pass rebates to members at point of sale; ban spread pricing
Under the standard offering, ESI must enable members to receive the benefit of any rebate or discount at the pharmacy point of sale (without charging a fee beyond actual pre‑funding costs), may not provide plan sponsors with rebate guarantees, and may not use spread pricing where the PBM charges a different amount than it reimburses pharmacies.
Pay small retail pharmacies actual cost plus fee
ESI must offer a standard contract to retail community pharmacies (businesses with three or fewer retail stores) that compensates them based on their actual drug acquisition cost plus a dispensing fee, pays extra for non‑dispensing services, and does not exclude any retail community pharmacy willing to accept the terms.
Insulin Patient Assurance Program access
If a plan sponsor adopts a formulary that includes an insulin product covered by ESI's Patient Assurance Program, ESI must provide full access to that Program for all members unless the plan sponsor opts out in writing, offering extra protection against high out‑of‑pocket insulin costs.
Require low‑WAC drug versions on formularies
ESI must place low‑WAC (lower list‑price) versions of drugs on its four standard commercial formularies without disadvantaging them compared to high‑WAC versions, except when the low‑WAC version is higher net cost or unavailable in sufficient supply. The change is intended to address situations where list‑price choices increased patients' out‑of‑pocket costs.
Require annual drug cost and claims transparency
ESI must provide plan sponsors as part of its standard offering an annual report showing each drug's costs, pharmacy claim‑level reporting, and any compensation paid to consultants or brokers related to pharmacy benefit services.
Delink manufacturer pay from list price
For ESI's standard offering, compensation from drug manufacturers to ESI may not be based, directly or indirectly, on a drug's list price (WAC). The change is intended to remove incentives tied to higher list prices.
Reshore ESI's group purchasing organization
The Proposed Order requires ESI to move its group purchasing organization (GPO) Ascent from Switzerland to the United States.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-11635 — Ascension Health Alliance; Analysis of Proposed Agreement Containing Consent Orders To Aid Public Comment
The Federal Trade Commission is reviewing a deal with Ascension Health Alliance to stop unfair competition practices. This affects Ascension and its healthcare partners, aiming to keep the market fair and open. People have until July 10, 2026, to share their thoughts before the deal is finalized—no money changes hands, just rules to play fair.
2026-11114 — Privacy Act of 1974; System of Records
The FTC is updating its Privacy Act records notice to make it clearer and more accurate. This affects anyone whose info is in the FTC’s systems, like consumer complaints or Do Not Call lists. The changes take effect on June 3, 2026, with no extra costs involved—just better info protection and transparency!
2026-10546 — MindSift LLC; Analysis of Proposed Consent Order To Aid Public Comment
MindSift LLC is facing claims for unfair or tricky business practices, and they’ve agreed to stop these actions through a new deal with the Federal Trade Commission. The public can share their thoughts on this agreement until June 29, 2026. This means MindSift must change how they operate soon, or face further action.
2026-10548 — CMG Media Corporation; Analysis of Proposed Consent Order To Aid Public Comment
CMG Media Corporation is facing charges for unfair or tricky business practices, and they’ve agreed to stop these actions through a new deal with the government. People can share their thoughts on this agreement until June 29, 2026. This means CMG Media must change how they operate, and the public gets a say before it’s final.
2026-10547 — 1010 Digital Works LLC; Analysis of Proposed Consent Order To Aid Public Comment
1010 Digital Works LLC is facing charges for unfair or tricky business practices, and they’ve agreed to stop these actions under a new deal. The public can share their thoughts on this agreement until June 29, 2026. This means 1010 Digital must clean up its act, and everyone gets a say before the deal is final.
2026-09704 — Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
If companies want to merge or buy each other, they usually have to wait a set time so the government can check for any problems. This notice says some companies got the green light to skip that wait early between April 1 and April 30, 2026, meaning their deals can close faster. This helps businesses save time and money while the government signals no issues with these deals.
Previous / Next Documents
Previous: 2026-02840 — Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC updated the names on its sanctions lists to fix small errors and keep things clear. These changes affect people and groups already on the list, making sure the info is accurate and up-to-date. No new sanctions or money changes, just smarter records as of September 23, 2025.
Next: 2026-02846 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in March 2026 to review and evaluate grant applications related to health and science research. These meetings keep sensitive info private, protecting personal and trade secrets. Scientists and researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.